Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
1942 The University of Texas at El Paso (143830)
Principal Investigator: Qin,Yong
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 68,554
Exceeds $250,000 (Is it flagged?): No
Start and End Dates: 3/1/23 - 10/31/23
Restricted Research: YES
Academic Discipline: Pharmacy
Department, Center, School, or Institute: Pharmacy
Title of Contract, Award, or Gift: Novel PHD2/HDACs hybrid inhibitors as therapeutics for advanced cervical cancer
Name of Granting or Contracting Agency/Entity:
LIZANELL AND COLBERT COLDWELL FOUNDATION
Program Title: #N/A
Note:
The current frontline standard treatment for recurrent or metastatic cervical cancer is the combination therapy of bevacizumab targeting the blood supply that feeds tumors and chemotherapy platinum doublets (cisplatin/carboplatin and paclitaxel), which showed about a 50% response rate in the clinic. However, both bevacizumab and cisplatin have strong toxicities for the kidney, which can cause acute kidney injury (AKI). Since nearly 60% of patients with cancer have some form of kidney disease, the anticancer drug-induced AKI can progress to end-stage kidney failure and may also increase the risk of death. Thus, there is an urgent need for preventive measures to lower the kidney toxicity of current chemotherapies for cervical cancer. In the proposed study, we will test our in-house novel PHD2-HDACs hybrid inhibitor, 31c, as a kidney protector against cisplatin and bevacizumab-induced kidney injury and an effective targeted therapy to combat tumor progression for advanced cervical cancer. This study will lay a foundation to further develop 31c as an effective therapy for advanced ovarian cancer and non-small-cell lung cancer (NSCLC), known to be treated with bevacizumab and platinum doublets.
Discussion: No discussion notes